Predictors of short term mortality in heart failure - Insights from the Euro Heart Failure survey

International Journal of Cardiology

Volumn 138, Issue 1, 2010, Pages 63-69

  Velavan, Periaswamy ^a   Khan, Nasrin K ^a   Goode, Kevin ^a   Rigby, Alan S ^a   Loh, Poay H ^a   Komajda, Michel ^b   Follath, Ferenc ^c   Swedberg, Karl ^d   Madeira, Hugo ^e   Cleland, John G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Cholesterol; Euro Heart Failure survey; Heart failure; Mortality; Risk score

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; INOTROPIC AGENT; LOOP DIURETIC AGENT; NITRIC ACID DERIVATIVE; SPIRONOLACTONE; STATINE DERIVATIVE; THIAZIDE DIURETIC AGENT; WARFARIN;

AGED; ANEMIA; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DIABETES MELLITUS; DRUG BLOOD LEVEL; ECG ABNORMALITY; ECHOCARDIOGRAPHY; FEMALE; GROUPS BY AGE; HEALTH SURVEY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPONATREMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MORTALITY; MULTICENTER STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; QRS COMPLEX; SCORING SYSTEM; SEX RATIO; SINGLE BLIND PROCEDURE; SODIUM BLOOD LEVEL; SYSTOLIC DYSFUNCTION; VALVULAR HEART DISEASE;

ADRENERGIC BETA-ANTAGONISTS; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CALCIUM CHANNEL BLOCKERS; CARDIOTONIC AGENTS; CHOLESTEROL; COMORBIDITY; EUROPE; FEMALE; FIBRINOLYTIC AGENTS; HEALTH SURVEYS; HEART FAILURE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 70949095552     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.08.004     Document Type: Article

References (33)

1. Khand A., Gemmel I., Clark A.L., et al. Is the prognosis of heart failure improving?. J Am Coll Cardiol 36 (2000) 2284-2286
2. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham heart study. Circulation 106 (2002) 3068-3072
3. Bluminsk G.S., Knetsh A.M., Sturkenboom M.C., et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. Eur Heart J 25 (2004) 1614-1619
4. Brown A.M., and Cleland J.G. Influence of concominant disease on patterns of hospitalisation in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J 19 (1998) 1063-1069
5. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
6. Cleland J.G., Thygesen K., Uretsky B.F., et al. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J 22 (2001) 1601-1612
7. Fonarow G.C., Adams K.F., Abraham W.T., et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293 (2005) 572-580
8. Swedberg K., Cleland J., Dargie H., et al. ESC Guidelines for the diagnosis and treatment of chronic heart failure; executive summary (update 2005). Eur Heart J 26 (2005) 1115-1140
9. Komajda M., Lapuerta P., Hermans N., et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur. Heart J 26 (2005) 1653-1659
10. Cleland J.G.F., Swedberg K., Cohen-Solal A., et al. The Euro Heart Failure survey of the EUROHEART survey programme: a survey on the quality of care among patients with heart failure in Europe. Eur J Heart Fail 2 (2000) 123-132
11. Cleland J.G.F., Swedberg K., Follath F., et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe: Part 1: patient characteristics and diagnosis. Eur Heart J 24 (2003) 442-463
12. Komajda M., Follath F., Swedberg K., et al. The Study Group of Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe: Part 2: treatment. Eur Heart J 24 (2003) 464-474
13. Lenzen M.J., Boersma E., Reimer W.J., et al. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J 24 (2005) 2706-2713
14. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med 314 (1986) 1547-1552
15. Taylor L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
16. Cleland J.G., Findlay I., Jafri S., et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 148 (2004) 157-164
17. Massie B.M., Krol W.F., Ammon S.E., et al. The warfarin and antiplatelet therapy in heart failure trial (WATCH) rationale, design, and baseline patient characteristics. J Card Fail 10 (2004) 101-112
18. Kalantar-Zadeh K., Block G., Horwich T., et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. Journal of the American College of Cardiology 43 (2004) 1439-1444
19. Sola S., Mir M.Q., Lerakis S., et al. Atorvastatin improves left ventricular function and serum markers of inflammation in non ischaemic heart failure. J Am Coll Cardiol 47 (2006) 332-337
20. Vrtovec B., Okrajsek R., Golicnik A., et al. Atorvastatin therapy increases heart rate variability, decreases QT variability and shortens QTc interval in patients with advanced chronic heart failure. J Card Fail 11 (2005) 684-690
21. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
22. Thackray S., Easthaugh J., Freemantle N., et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 4 (2002) 515-529
23. Konstam M.A., Gheorghiade M., Burnett Jr. J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 (2007) 1319-1331
24. McAlister F.A., Ezekowitz J., Tonelli M., et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109 (2004) 1004-1009
25. Hillege H.L., Nitsch D., Pfeffer M.A., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113 (2006) 671-678
26. Dittrich H.C., Gupta D.K., Hack T.C., et al. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 8 (2007) 609-617
27. Givertz M.M., Massie B.M., Fields T.K., et al. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 50 (2007) 1551-1560
28. Cleland J.G., Coletta A.P., Abdellah A.T., et al. Clinical trials update from Heart Rhythm 2007 and Heart Failure 2007: CARISMA, PREPARE, DAVID II, SAVE-PACE, PROTECT and AREA-IN-CHF. Eur J Heart Fail 8 (2007) 850-853
29. Lindenfield J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 149 (2005) 391-401
30. Sandgren P.E., Murray A.M., Herzog C.A., et al. Anemia and new onset congestive heart failure in the general medicare population. J Card Fail 11 (2005) 99-105
31. Mancini D.M., Katz S.D., Lang C.C., et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107 (2003) 294-299
32. Remme W.J., McMurray J.J.V., Hobbs F.D.R., et al., for the SHAPE Study Group. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur. Heart J. (2008) 10.1093/eurheartj/ehn196 Advance access published on May 31
33. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150